Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Voyager Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VYGR
Nasdaq
8731
https://www.voyagertherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Voyager Therapeutics Inc
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
- Apr 22nd, 2024 8:30 pm
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
- Apr 16th, 2024 11:00 am
Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
- Apr 9th, 2024 6:46 pm
Buy Voyager Stock, Analyst Says. The Little Biotech Could Have Big Breakthroughs.
- Mar 30th, 2024 7:00 am
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mar 26th, 2024 8:01 pm
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
- Mar 13th, 2024 11:00 am
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
- Mar 9th, 2024 6:09 pm
Analysts Just Made A Major Revision To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Forecasts
- Mar 4th, 2024 10:32 am
Q4 2023 Voyager Therapeutics Inc Earnings Call
- Feb 29th, 2024 4:09 pm
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Earnings Call Transcript
- Feb 29th, 2024 2:54 pm
Voyager Therapeutics Inc (VYGR) Announces Strong Year-End Financials with Significant Cash Position
- Feb 28th, 2024 9:41 pm
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
- Feb 28th, 2024 9:01 pm
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
- Feb 26th, 2024 12:00 pm
Novavax (NVAX) Surges 8.4%: Is This an Indication of Further Gains?
- Feb 26th, 2024 7:46 am
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
- Feb 21st, 2024 12:00 pm
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
- Feb 20th, 2024 12:00 pm
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
- Feb 7th, 2024 12:00 pm
While institutions own 30% of Voyager Therapeutics, Inc. (NASDAQ:VYGR), individual investors are its largest shareholders with 42% ownership
- Jan 26th, 2024 1:44 pm
Financial Frontrunners: 3 Stocks Where the Big Money Is Moving in 2024
- Jan 12th, 2024 3:09 am
Voyager Therapeutics Announces Pricing of Public Offering
- Jan 5th, 2024 3:45 am
Scroll